Eugia Pharma receives USFDA Approval for Glycopyrrolate Injection

Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Glycopyrrolate Injection .

Indications for this product include preoperative antimuscarinic to reduce salivary, trachea­bronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation.

Adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated.

Refer to package insert for full prescribing information.